FTC OKs Teva-Barr Pharma Merger

WASHINGTON (CN) - Teva Pharmaceuticals will buy rival generic drugmaker Barr Pharmaceuticals for $8.9 billion, but the merger partners will have to sell assets in 29 U.S. markets to competitors Watson and Qualitest Pharmaceuticals, the FTC said in a settled complaint. Teva and Barr will have to sell assets that include generic drugs used to treat acid reflux, cancer, bacterial infections, diabetes and depression.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit